Skip to main content
logo
Generate Biomedicines, Inc. (GENB)
NASDAQ: GENB · Real-Time Price · USD
15.03
-0.06 (-0.40%)
At close: Aug 13, 2026, 4:00 PM EDT
15.13
+0.10 (0.67%)
Pre-market: Aug 14, 2026, 5:41 AM EDT

Generate Biomedicines Balance Sheet

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Cash & Equivalents
135.36121.65176.27
Short-Term Investments
322.0699.85217.36
Cash & Short-Term Investments
457.42221.5393.63
Cash Growth
16.20%-43.73%-
Accounts Receivable
--0.31
Other Current Assets
12.8412.8713.56
Total Current Assets
470.25234.37407.49
Net Property, Plant & Equipment
82.3889.01101.07
Other Long-Term Assets
9.066.819.7
Total Assets
561.69330.18518.26

Liabilities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Accounts Payable
5.653.845.67
Accrued Expenses
25.242.1621.77
Current Portion of Leases
13.6215.0116.72
Unearned Revenue
12.1721.1942.43
Other Current Liabilities
--0.05
Total Current Liabilities
56.6482.286.63
Long-Term Leases
49.0153.5260.26
Other Long-Term Liabilities
-5.8316.62
Total Long-Term Liabilities
49.0159.3576.87
Total Liabilities
105.65141.55163.5

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Common Stock
0.130.030.03
Additional Paid-in Capital
1,26160.1938.47
Accumulated Other Comprehensive Income
-0.130.110.12
Retained Earnings
-804.99-676.29-473.14
Total Common Shareholders' Equity
456.05-615.97-434.52
Minority Interest
-804.59789.28
Shareholders' Equity
456.05188.63354.76
Total Liabilities & Equity
561.69330.18518.26

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Total Debt
62.6368.5376.97
Net Cash (Debt)
394.79152.97316.66
Net Cash Growth
24.67%-51.69%-
Net Cash Per Share
6.094.649.87
Book Value
456.05-615.97-434.52
Book Value Per Share
7.04-18.68-13.54
Tangible Book Value
456.05-615.97-434.52
Tangible Book Value Per Share
7.04-18.68-13.54
SEC Filings: 10-K · 10-Q